Related Experiment Video

Updated: May 5, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K

Lowered cancer risk with ACE inhibitors/ARBs: a population-based cohort study

Yi-Ying Chiang1, Kuen-Bao Chen, Tung-Han Tsai

  • 1Department of Anesthesiology, China Medical University Hospital, Taichung, Taiwan; Department of Health Services Administration, China Medical University, Taichung, Taiwan.

Journal of Clinical Hypertension (Greenwich, Conn.)
|December 6, 2013
PubMed

Insights

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) used for hypertension did not increase cancer risk. This study found these medications may actually decrease overall cancer risk in patients.

Area of Science:

  • Cardiovascular Pharmacology
  • Oncology
  • Epidemiology

Background:

  • Conflicting reports exist regarding the association between ACE inhibitors/ARBs and cancer risk.
  • Essential hypertension is a common condition often treated with ACE inhibitors/ARBs.

Purpose of the Study:

  • To investigate the association between ACE inhibitors/ARBs and cancer development in patients with essential hypertension.
  • To clarify the conflicting evidence on cancer risk with these antihypertensive medications.

Main Methods:

  • Retrospective cohort study utilizing the Taiwan National Health Insurance Research Database.
  • Inclusion of 297,688 patients with essential hypertension, stratified into ACE inhibitor, ARB, and control groups.
  • Matched analysis to observe cancer occurrence over time.

Main Results:

  • ACE inhibitor use was associated with a reduced hazard ratio for cancer (0.51) compared to controls.
  • ARB use showed a reduced hazard ratio for cancer (0.8) compared to controls.
  • No increased cancer risk was observed with regular use of ACE inhibitors/ARBs.

Conclusions:

  • Regular use of ACE inhibitors and ARBs for essential hypertension is not linked to an increased risk of cancer.
  • These medications may be associated with a decreased overall cancer risk.

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.1K

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.5K
Cancer Prevention02:59

Cancer Prevention

2.6K